Pharmacokinetic characterization of hydroxylpropyl-β-cyclodextrin- included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza)

Xenobiotica

Volumn 38, Issue 4, 2008, Pages 382-398

  Pan, Y ^a   Bi, H C ^a   Zhong, G P ^a   Chen, X ^a   Zuo, Z ^b   Zhao, L Z ^a   Gu, L Q ^a   Liu, P Q ^a   Huang, Z Y ^a   Zhou, S F ^c   Huang, M ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^c RMIT UNIVERSITY   (Australia)

Author keywords

Bioavailability; Cryptotanshinone; Elimination; Inclusion complex; Tanshinone IIA; Tissue distribution

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CRYPTOTANSHINONE; TANSHINONE;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; FEMALE; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; RAT; SALVIA MILTIORRHIZA; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BETA-CYCLODEXTRINS; CARDIOVASCULAR AGENTS; DOGS; DRUGS, CHINESE HERBAL; DRUGS, INVESTIGATIONAL; FEMALE; MALE; PHENANTHRENES; PHENANTHROLINES; RATS; SALVIA MILTIORRHIZA; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS; RATTUS; SALVIA MILTIORRHIZA;

EID: 40749148985     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701827685     Document Type: Article

References (18)

1. Bi HC, Law FC, Zhong GP, Xu CS, Pan Y, Ding L, Chen X, Zhao LZ, Xu Q, Huang M. 2007. Study of tanshinone IIA tissue distribution in rat by liquid chromatography-tandem mass spectrometry method. Biomedicine and Chromatography 21:473-479.
2. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharmacology Research 10:1093-1095.
3. Don MJ, Shen CC, Syu WJ, Ding YH, Sun CM. 2006. Cytotoxic and aromatic constituents from Salvia miltiorrhiza. Phytochemistry 67:497-503.
4. Hao H, Wang G, Cui N, Li J, Xie L, Ding Z. 2006a. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Medica 72:1311-1317.
5. Hao H, Wang G, Li P, Li J, Ding Z. 2006b. Simultaneous quantification of cryptotanshinone and its active metabolite tanshinone IIA in plasma by liquid chromatography/tandem mass spectrometry (LC-MS/MS). Journal of Pharmacology and Biomedical Analysis 40:382-388.
6. Hori R, Okumura K, Yoshida H. 1987. Binding of basic drugs to rat lung mitochondria. Pharmacology Research 4:142-146.
7. Hur JM, Shim JS, Jung HJ, Kwon HJ. 2005. Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Experimental Molecular Medicine 37:133-137.
8. Jin DZ, Yin LL, Ji XQ, Zhu XZ. 2006. Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression. European Journal of Pharmacology 549:166-172.
9. Kang BY, Chung SW, Kim SH, Ryu SY, Kim TS. 2000. Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 49:355-361.
10. Luo X, Xu YH, Chen B, Gu LQ, Huang M, Liu PQ. 2005. Solubilization on cryptotanshinone by hydroxypropylb-cyclodextrin and preparation of their inclusion compound. Zhongguo Zhongyao Zazhi 30:1328-1331.
11. Nishiura A, Murakami T, Higashi Y, Yata N. 1988. Role of phosphatidylserine in the cellular and subcellular lung distribution of quinidine in rats. Pharmacology Research 5:209-213.
12. Roffey SJ, Obach RS, Gedge JI, Smith DA. 2007. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metabolism Reviews 39:17-43.
13. Song M, Hang TJ, Zhang Zh X, Du R, Chen J. 2005. Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography- tandem mass spectrometry. Journal of Chromatography B: Analytical Technology and Biomedical Life Sciences 827:205-209.
14. Wang AM, Sha SH, Lesniak W, Schacht J. 2003. Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrobial Agents and Chemotherapy 47:1836-1841.
15. Xie MZ, Shen ZF, 1983. [Absorption, distribution, excretion and metabolism of cryptotanshinone]. Yao Xue Xue Bao 18:90-96.
16. Xue M, Cui Y, Wang HQ, Luo YJ, Zhang B, Zhou ZT. 1999. [Pharmacokinrtics of cryptotanshinone and its metabolite in pigs]. Yao Xue Xue Bao 34:81-84.
17. Zhang J, Huang M, Guan S, Bi HC, Pan Y, Duan W, Chan SY, Chen X, Hong YH, Bian JS, Yang HY, Zhou S. 2006. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. Journal of Pharmacology and Experimental Therapy 317:1285-1294.
18. Zhou L, Zuo Z, Chow MS. 2005. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. Journal of Clinical Pharmacology 45:1345-1359.